Inscrutability arguments threaten to reduce interpretationistmetasemantic theories to absurdity. Can we find some way to block the arguments? A highly influential proposal in this regard is David Lewis’ ‘eligibility’ response: some theories are better than others, not because they fit the data better, but because they are framed in terms of more natural properties. The purposes of this paper ar...

On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved aducanumab, an amyloid beta-directed monoclonal antibody, as a new treatment for Alzheimer's disease (AD),1 taking advantage of Accelerated Approval program. The aducanumab effect on beta plaques2 was deemed to predict benefits patients and, thus, considered approvable surrogate endpoint. Nevertheless, there are residual unce...